Phase II COBRE CNTN

Information

  • Research Project
  • 10271794
  • ApplicationId
    10271794
  • Core Project Number
    P20GM109025
  • Full Project Number
    2P20GM109025-06A1
  • Serial Number
    109025
  • FOA Number
    PAR-19-312
  • Sub Project Id
    6597
  • Project Start Date
    9/1/2015 - 9 years ago
  • Project End Date
    6/30/2026 - a year from now
  • Program Officer Name
  • Budget Start Date
    7/1/2021 - 3 years ago
  • Budget End Date
    6/30/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    06
  • Suffix
    A1
  • Award Notice Date
    9/6/2021 - 3 years ago

Phase II COBRE CNTN

SUMMARY/ABSTRACT Clinical and Translational Research Core (CTRC) The Clinical and Translational Research Core (CTRC) provides the infrastructure for neurodegenerative disease (NDD) clinical research within the Center for Neurodegenerative and Translational Neuroscience (CNTN). In Phase 1, the Core recruited, characterized, and retained a clinical cohort consisting of more than 190 ?deeply phenoyped? research participants across five diagnostic groups: mild cognitive impairment (MCI), mild Alzheimer?s disease (AD), Parkinson?s disease (PD) with no cognitive impairment (PD-NC), PD with mild cognitive impairment (PD-MCI), and cognitively normal controls (CNC). Data from this cohort directly supported the research goals of 5 projects in Phase 1, as well several other collaborations. In Phase 2, the core will extend the study up to ten years. As in Phase 1, the CTRC will provide each project leader with operational and regulatory support, project management, and research instruction that will help advance them toward the goal of independent funding. A notable enhancement of the Clinical Core in Phase 2 includes a focus on the role of neuroinflammation in NDD. The CTRC?s multimodal approach to neuroinflammation (including neuroimaging, blood-based biomarkers, genetics, and clinical assessments) represents one of the first comprehensive databases in the field of NDD. In addition to sustaining the clinical core, the CTRC will focus on increasing participation rates of traditionally underrepresented patient populations. Participation will be facilitated through expansion of our education and outreach program. This program, which was implemented in Phase 1, is guided by input from a Community Advisory Board (CAB) and includes an innovative education and outreach website (Healthybrains.org). Finally, the core will also establish the first biobank in Southern Nevada at the University of Nevada-Las Vegas (UNLV) under the direction of Dr. Jefferson Kinney. This new resource will store, analyze, and provide expertise in the evaluation of non-clinical and clinical biospecimens. In addition to supporting the currently proposed projects, a number of additional COBRE and non-COBRE collaborators will access this valuable resource. The CTRC has formative and summative assessments imbedded within in that will insure success in achieving its specific aims.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    P20
  • Administering IC
    GM
  • Application Type
    2
  • Direct Cost Amount
    601808
  • Indirect Cost Amount
    217192
  • Total Cost
  • Sub Project Total Cost
    819000
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    NIGMS:819000\
  • Funding Mechanism
    RESEARCH CENTERS
  • Study Section
    ZGM1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CLEVELAND CLINIC FOUNDATION
  • Organization Department
  • Organization DUNS
    017730458; 809775336
  • Organization City
    CLEVELAND
  • Organization State
    OH
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    441950001
  • Organization District
    UNITED STATES